R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
Status:
Terminated
Trial end date:
2010-04-27
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of doxorubicin,
cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus rituximab in comparison
to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) plus rituximab in patients
aged from 60 to 65 years with non-previously treated diffuse large B-cell lymphoma as
measured by the event-free survival. The goal is to obtain a 10% increase of event-free
survival at 3 years.